CES Biotech is an in-silico biotech company. We use gene expression data to generate insights for biomedical research.

In early 2019, the co-founders of CES Biotech began an exploration into how gene expression is influenced by the shape of the space under which RNA transcription occurs. Over the course of their investigation, they invented a method to detect changes in gene expression which are due to changes in cell morphology and filed a provisional patent for the process.

The Chromosome Expressivity Scores (CES™) generated by their patent-pending process can be used to predict phenotypic traits associated with morphological pathology such as biological age. The CES™ biomarkers can also be used to identify sub-populations within abandoned late stage drug-trials for whom the treatment may still be effective. CES Biotech was formed to exploit the research and commercial applications associated with this technology.